Judging from the specific profits announced by related companies, Kexing Zhongwei Company accounts for a relatively large proportion, on the one hand, because the company has obvious advantages in the field of vaccines in COVID-19, and has obtained listing licenses from many countries and regions. On the other hand, because the company has established cooperative relations with many countries, it has supplied 2.8 billion doses of vaccines worldwide.

Profit model 1: Export COVID-19 vaccine Since the confirmed cases of COVID-19 appeared in many countries, many countries will seek COVID-19 vaccine. Although some countries have adopted completely different vaccination methods, residents in many countries are eager to get COVID-19 vaccine. It is difficult for some countries to produce and develop COVID-19 vaccine in the first time, which makes Kexing China and Victoria become partners of many countries. Exporting vaccines has brought more profits to the company, and the gross profit is increasing.

Profit model 2: Increase technology research and development COVID-19 vaccine production technology and research and development technology has never been a simple concept, but requires pharmaceutical companies to spend a lot of time and energy. Increasing technology research and development has become the development goal of Kexing Zhongwei Company. When the technology of developing COVID-19 vaccine keeps breaking through, the company has a particularly obvious technical advantage. Not only can COVID-19 vaccine be directly provided to many countries, but also technical cooperation can be carried out with many companies around the world. Over time, the company's popularity in the world is getting higher and higher, which has not only been recognized by residents around the world, but also made the company's profits increase smoothly.

Generally speaking, Chinese pharmaceutical enterprises are on the rise, especially a group of vaccine manufacturers headed by Kexing Zhongwei Company. They not only show the comprehensive strength of Chinese pharmaceutical enterprises, but also reflect the continuous improvement of medical technology in China. More importantly, free vaccination of COVID-19 vaccine for domestic residents can reduce the cost of vaccination for residents and ensure the safety of people's lives.